{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:17:40Z","timestamp":1757452660845,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014116","name":"Ontario Veterinary College, University of Guelph","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014116","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rna Diagnostics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Assessment of the efficacy of a multi-agent chemotherapy protocol in which cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) are administered in canine lymphoma is generally performed by physical measurement of lymph node diameter. However, no consistent correlation has been made with prognostic indicators and the length or absence of clinical remission based on lymph node size. RNA disruption measured mid-therapy has been correlated with increased disease-free survival in recent studies of human cancer and was assessed in this study of canine lymphoma patients. Fine needle aspirate samples were taken before treatment and at weeks 3, 6, and 11 of CHOP therapy. RNA was isolated from these samples and assessed using an Agilent Bioanalyzer. RNA disruption assay (RDA) analysis was performed on the data from the resulting electropherograms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>An increased RNA disruption index (RDI) score was significantly associated with improved progression-free survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Predicting the risk of early relapse during chemotherapy could benefit veterinary patients by reducing ineffective treatment and could allow veterinary oncologists to switch earlier to a more effective drug regimen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12917-019-2189-x","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T16:02:37Z","timestamp":1576512157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["RNA disruption indicates CHOP therapy efficacy in canine lymphoma"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1447-658X","authenticated-orcid":false,"given":"Amadeo M.","family":"Parissenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura B.","family":"Pritzker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Narendrula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirly Xiaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin Laura","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingchun","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Skowronski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Bienzle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Paul","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth P. H.","family":"Pritzker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda L.","family":"Coomber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"issue":"1","key":"2189_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hon.2017","volume":"31","author":"L Marconato","year":"2013","unstructured":"Marconato L, Gelain ME, Comazzi S. The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol Oncol. 2013;31(1):1\u20139.","journal-title":"Hematol Oncol"},{"issue":"4","key":"2189_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2460\/javma.238.4.501","volume":"238","author":"AB Flory","year":"2011","unstructured":"Flory AB, Rassnick KM, Erb HN, Garrett LD, Northrup NC, Selting KA, Phillips BS, Locke JE, Chretin JD. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007). J Am Vet Med Assoc. 2011;238(4):501\u20136.","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2189_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1476-5829.2010.00224.x","volume":"8","author":"KM Rassnick","year":"2010","unstructured":"Rassnick KM, Bailey DB, Malone EK, Intile JL, Kiselow MA, Flory AB, Barlow LL, Balkman CE, Barnard SM, Waite AH. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs. Vet Comp Oncol. 2010;8(4):243\u201353.","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"2189_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","volume":"8","author":"DM Vail","year":"2010","unstructured":"Vail DM, Michels GM, Khanna C, Selting KA, London CA. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2010;8(1):28\u201337.","journal-title":"Vet Comp Oncol"},{"issue":"2","key":"2189_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/01652176.2016.1152633","volume":"36","author":"M Zandvliet","year":"2016","unstructured":"Zandvliet M. Canine lymphoma: a review. The Vet Q. 2016;36(2):76\u2013104.","journal-title":"The Vet Q"},{"key":"2189_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.vetimm.2017.07.008","volume":"191","author":"N Deravi","year":"2017","unstructured":"Deravi N, Berke O, Woods JP, Bienzle D. Specific immunotypes of canine T cell lymphoma are associated with different outcomes. Vet Immunol Immunopathol. 2017;191:5\u201313.","journal-title":"Vet Immunol Immunopathol"},{"issue":"Suppl 1","key":"2189_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/vco.12127","volume":"14","author":"V Nerschbach","year":"2016","unstructured":"Nerschbach V, Eberle N, Joetzke AE, Hoeinghaus R, Hungerbuehler S, Mischke R, Nolte I, Betz D. Splenic and hepatic ultrasound and cytology in canine lymphoma: effects of findings on stage migration and assessment of prognosis. Vet Comp Oncol. 2016;14(Suppl 1):82\u201394.","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"2189_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.tvjl.2015.04.032","volume":"205","author":"SL Wang","year":"2015","unstructured":"Wang SL, Lee JJ, Liao AT. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma. Veterinary journal (London, England : 1997). 2015;205(1):69\u201373.","journal-title":"Veterinary journal (London, England : 1997)"},{"issue":"4","key":"2189_CR9","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/vco.12263","volume":"15","author":"KM Curran","year":"2017","unstructured":"Curran KM, Schaffer PA, Frank CB, Lana SE, Hamil LE, Burton JH, Labadie J, Ehrhart EJ, Avery PR. BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy. Vet Comp Oncol. 2017;15(4):1269\u201379.","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2189_CR10","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1111\/vco.12296","volume":"15","author":"SJ Fontaine","year":"2017","unstructured":"Fontaine SJ, McCulloch E, Eckersall PD, Haining H, Patterson Kane JC, Morris JS. Evaluation of the modified Glasgow prognostic score to predict outcome in dogs with newly diagnosed lymphoma. Vet Comp Oncol. 2017;15(4):1513\u201326.","journal-title":"Vet Comp Oncol"},{"key":"2189_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1186\/1471-2407-14-657","volume":"14","author":"SA Johnston","year":"2014","unstructured":"Johnston SA, Thamm DH, Legutki JB. The immunosignature of canine lymphoma: characterization and diagnostic application. BMC Cancer. 2014;14:657.","journal-title":"BMC Cancer"},{"issue":"2","key":"2189_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1040638717743280","volume":"30","author":"OR Sierra Matiz","year":"2018","unstructured":"Sierra Matiz OR, Santilli J, Anai LA, Da Silva MCL, Sueiro FA, Sequeira JL, Magalhaes LF, Magalhaes GM, Tinucci Costa M, Calazans SG. Prognostic significance of Ki67 and its correlation with mitotic index in dogs with diffuse large B-cell lymphoma treated with 19-week CHOP-based protocol. J Vet Diagn Investig. 2018;30(2):263\u20137.","journal-title":"J Vet Diagn Investig"},{"key":"2189_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcpa.2018.04.005","volume":"161","author":"B Miniscalco","year":"2018","unstructured":"Miniscalco B, Poggi A, Martini V, Morello E, Sulce M, Melega M, Borrelli A, Tarducci A, Riondato F. Flow Cytometric characterization of S-phase fraction and Ploidy in lymph node aspirates from dogs with lymphoma. J Comp Pathol. 2018;161:34\u201342.","journal-title":"J Comp Pathol"},{"issue":"9","key":"2189_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrclinonc.2016.35","volume":"13","author":"L De Mattos-Arruda","year":"2016","unstructured":"De Mattos-Arruda L, Shen R, Reis-Filho JS, Cortes J. Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol. 2016;13(9):566\u201379.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2189_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12032-016-0740-1","volume":"33","author":"M Alsharedi","year":"2016","unstructured":"Alsharedi M, Gress T, Dotson J, Elmsherghi N, Tirona MT. Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer. Med Oncol (Northwood, London, England). 2016;33(3):27.","journal-title":"Med Oncol (Northwood, London, England)"},{"issue":"8","key":"2189_CR16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/14740338.2016.1182493","volume":"15","author":"G Giordano","year":"2016","unstructured":"Giordano G, Spagnuolo A, Olivieri N, Corbo C, Campagna A, Spagnoletti I, Pennacchio RM, Campidoglio S, Pancione M, Palladino L, et al. Cancer drug related cardiotoxicity during breast cancer treatment. Expert Opin Drug Saf. 2016;15(8):1063\u201374.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2189_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-009-0531-x","volume":"119","author":"AM Parissenti","year":"2010","unstructured":"Parissenti AM, Chapman JA, Kahn HJ, Guo B, Han L, O'Brien P, Clemons MP, Jong R, Dent R, Fitzgerald B, et al. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2010;119(2):347\u201356.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2189_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-015-3498-9","volume":"153","author":"AM Parissenti","year":"2015","unstructured":"Parissenti AM, Guo B, Pritzker LB, Pritzker KP, Wang X, Zhu M, Shepherd LE, Trudeau ME. Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy. Breast Cancer Res Treat. 2015;153(1):135\u201344.","journal-title":"Breast Cancer Res Treat"},{"key":"2189_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12885-016-2197-1","volume":"16","author":"R Narendrula","year":"2016","unstructured":"Narendrula R, Mispel-Beyer K, Guo B, Parissenti AM, Pritzker LB, Pritzker K, Masilamani T, Wang X, Lanner C. RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines. BMC Cancer. 2016;16:146.","journal-title":"BMC Cancer"},{"issue":"1","key":"2189_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10549-014-2840-y","volume":"144","author":"C Foroni","year":"2014","unstructured":"Foroni C, Milan M, Strina C, Cappelletti M, Fumarola C, Bonelli M, Bertoni R, Ferrero G, Maldotti M, Takano E, et al. Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the \"biological window therapy\". Breast Cancer Res Treat. 2014;144(1):113\u201321.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2189_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1530\/ERC-14-0088","volume":"21","author":"A Neschadim","year":"2014","unstructured":"Neschadim A, Pritzker LB, Pritzker KP, Branch DR, Summerlee AJ, Trachtenberg J, Silvertown JD. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts. Endocr Relat Cancer. 2014;21(3):459\u201371.","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2189_CR22","doi-asserted-by":"publisher","first-page":"djw111","DOI":"10.1093\/jnci\/djw111","volume":"108","author":"Sinead Toomey","year":"2016","unstructured":"Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, et al. RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Natl Cancer Inst. 2016;108(8).","journal-title":"Journal of the National Cancer Institute"},{"issue":"6","key":"2189_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1740-8261.2009.01612.x","volume":"50","author":"J Lawrence","year":"2009","unstructured":"Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas DB, Vail DM. Use of 3\u2032-deoxy-3\u2032-[18F] fluorothymidine PET\/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma. Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association. 2009;50(6):660\u20138.","journal-title":"Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association"},{"issue":"2","key":"2189_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1740-8261.2009.01520.x","volume":"50","author":"AK LeBlanc","year":"2009","unstructured":"LeBlanc AK, Jakoby BW, Townsend DW, Daniel GB. 18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor. Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association. 2009;50(2):215\u201323.","journal-title":"Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association"},{"key":"2189_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tvjl.2016.05.012","volume":"215","author":"JY Masahiko Sato","year":"2016","unstructured":"Masahiko Sato JY. Yuko Goto-Koshino, Askuka Setoguchi, Masashi Takahashi, Kenji Baba, Yasuhito Fujino, Koichi Ohno, Hajime Tsujimoto: minimal residual disease in canine lymphoma: an objective marker to assess tumour cell burden in remission. Vet J. 2016;215:38\u201342.","journal-title":"Vet J"},{"key":"2189_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tvjl.2016.05.012","volume":"215","author":"M Sato","year":"2016","unstructured":"Sato M, Yamazaki J, Goto-Koshino Y, Setoguchi A, Takahashi M, Baba K, Fujino Y, Ohno K, Tsujimoto H. Minimal residual disease in canine lymphoma: An objective marker to assess tumour cell burden in remission. Vet J (London, England : 1997). 2016;215:38\u201342.","journal-title":"Vet J (London, England : 1997)"},{"issue":"5","key":"2189_CR27","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1364\/BOE.9.002214","volume":"9","author":"H Choi","year":"2018","unstructured":"Choi H, Li Z, Sun H, Merrill D, Turek J, Childress M, Nolte D. Biodynamic digital holography of chemoresistance in a pre-clinical trial of canine B-cell lymphoma. Biomed Opt Express. 2018;9(5):2214\u201328.","journal-title":"Biomed Opt Express"},{"key":"2189_CR28","doi-asserted-by":"crossref","unstructured":"Ali Samkari WC, Amadeo Parissenti, Laura Pritzker, Nora Trabulsi, mark Basik, Jean-Francois Boileau: Tumor RNA disruption index as a tool to predict response to neoadjuvant chemotherapy in breast cancer: optimizing timing of biopsy. In: San Antonio Breast Cancer Symposium. San Antonio, Texas, USA; 2016.","DOI":"10.1158\/1538-7445.SABCS16-P1-09-19"},{"issue":"18","key":"2189_CR29","doi-asserted-by":"publisher","first-page":"13967","DOI":"10.1074\/jbc.275.18.13967","volume":"275","author":"D Nadano","year":"2000","unstructured":"Nadano D, Sato TA. Caspase-3-dependent and -independent degradation of 28 S ribosomal RNA may be involved in the inhibition of protein synthesis during apoptosis initiated by death receptor engagement. J Biol Chem. 2000;275(18):13967\u201373.","journal-title":"J Biol Chem"},{"issue":"8","key":"2189_CR30","doi-asserted-by":"publisher","first-page":"17611","DOI":"10.3390\/ijms160817611","volume":"16","author":"MA Siddiqui","year":"2015","unstructured":"Siddiqui MA, Mukherjee S, Manivannan P, Malathi K. RNase L cleavage products promote switch from autophagy to apoptosis by Caspase-mediated cleavage of Beclin-1. Int J Mol Sci. 2015;16(8):17611\u201336.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2189_CR31","doi-asserted-by":"publisher","first-page":"e34194","DOI":"10.1371\/journal.pone.0034194","volume":"7","author":"F Wen","year":"2012","unstructured":"Wen F, Zhou R, Shen A, Choi A, Uribe D, Shi J. The tumor suppressive role of eIF3f and its function in translation inhibition and rRNA degradation. PLoS One. 2012;7(3):e34194.","journal-title":"PLoS One"},{"key":"2189_CR32","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2147\/DDDT.S49584","volume":"8","author":"M Cekanova","year":"2014","unstructured":"Cekanova M, Rathore K. Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Des Dev Ther. 2014;8:1911\u201321.","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"2189_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/imr.12238","volume":"263","author":"KL Richards","year":"2015","unstructured":"Richards KL, Suter SE. Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma? Immunol Rev. 2015;263(1):173\u201391.","journal-title":"Immunol Rev"},{"issue":"9","key":"2189_CR34","doi-asserted-by":"publisher","first-page":"e72591","DOI":"10.1371\/journal.pone.0072591","volume":"8","author":"MA Mudaliar","year":"2013","unstructured":"Mudaliar MA, Haggart RD, Miele G, Sellar G, Tan KA, Goodlad JR, Milne E, Vail DM, Kurzman I, Crowther D, et al. Comparative gene expression profiling identifies common molecular signatures of NF-kappaB activation in canine and human diffuse large B cell lymphoma (DLBCL). PLoS One. 2013;8(9):e72591.","journal-title":"PLoS One"},{"issue":"1673","key":"2189_CR35","doi-asserted-by":"publisher","first-page":"20140233","DOI":"10.1098\/rstb.2014.0233","volume":"370","author":"Jessica Lawrence","year":"2015","unstructured":"Lawrence J, Cameron D, Argyle D: Species differences in tumour responses to cancer chemotherapy. Philosophical transactions of the Royal Society of London Series B, Biological sciences 2015, 370(1673).","journal-title":"Philosophical Transactions of the Royal Society B: Biological Sciences"},{"issue":"23","key":"2189_CR36","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1158\/1078-0432.CCR-18-1498","volume":"24","author":"JH Burton","year":"2018","unstructured":"Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, et al. NCI comparative oncology program testing of non-Camptothecin Indenoisoquinoline topoisomerase I inhibitors in naturally occurring canine lymphoma. Clin Cancer Res. 2018;24(23):5830\u201340.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2189_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cll.2015.05.008","volume":"35","author":"MJ Burkhard","year":"2015","unstructured":"Burkhard MJ, Bienzle D. Making sense of lymphoma diagnostics in small animal patients. Clin Lab Med. 2015;35(3):591\u2013607.","journal-title":"Clin Lab Med"},{"issue":"1","key":"2189_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.thj.6200013","volume":"1","author":"NL Harris","year":"2000","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting--Airlie house, Virginia, November, 1997. The Hematol J. 2000;1(1):53\u201366.","journal-title":"The Hematol J"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-2189-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-019-2189-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-2189-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:26:33Z","timestamp":1607991993000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-019-2189-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1186\/s12917-019-2189-x","relation":{},"ISSN":["1746-6148"],"issn-type":[{"type":"electronic","value":"1746-6148"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"26 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial underwent ethical review and was approved by the local Animal Care Committee of the University of Guelph, according to policies of the Canadian Council on Animal Care; drug treatment regimens were within the Standard of Care. Written client consent was obtained from all participants and clients were able to opt out of the study at any time. No experimental animals were used in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LP, RN, SW, LL, JP and KP are\/were employees of Rna Diagnostics. BG, KP, and AP are shareholders in Rna Diagnostics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}